ERBB2 and breast carcinoma: However, patients with advanced HER2+ breast cancer patients and brain metastases (excluding patients with LM) have a lower OS than those without (26.3‐30 vs 38‐44.6 months), indicating that despite advances in targeted therapy, patients with CNS involvement continue to have a worse prognosis.34, 35